Other

Myrexis, Inc.

Navigen, Inc.

University of Utah Research Foundation

Dr. Reddy's Laboratories, Incorporated

Myriad Genetics, Inc.

Dr. Reddy's Research Foundation

Myriad Pharmaceuticals, Inc.

Viogen Biosciences, LLC

Dr. Reddy's Laboraties Limited

Ashok Bajji

Braj Bhushan Lohray

Vidya Bhushan Lohray

Ranga Madhavan Gurram

Shivaramayya Kalchar

Rao Bheema Paraselli

Mark Shenderovich

Se-Ho Kim

Rajendra Tangallapally

Mark B Anderson

Kirill Ostanin

Richard Trovato

Daniel Wettstein

John A Vanecko

Benjamin Markovitz

Hariprasad Vankayalapati

Rajagopalan Ramanujam

Ranjan Chakrabarti

Dean Li

Alan L Mueller

Rachel M Slade

Jon Adam Willardsen

Eric Delmar

Ramanujam Rajagopalan

Esther Arranz

Jayasree M Srinivasan

Damon Papac

Christopher L Cioffi

Neil Moss

Chakrabarti Ranjan

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders.

Compounds and therapeutic uses thereof

Methods of treating vascular leak, vascular inflammation, angiogenesis, ocular disorders, and/or inflammatory disorders in a patient are provided. The methods can include administering an ADP-ribosylation factor 6 (ARF6) inhibitor to the patient. The present disclosure also relates to new chemical entities and pharmaceutical compositions including ARF6 inhibitors. The ARF6 inhibitor may be a prodrug of an ARF6 inhibitor.

ARF6 inhibitors and related methods

Disclosed herein are compounds and methods for inhibiting Arf6. Pharmaceutical compositions and methods for treating a subject with an inhibitor of Arf6 are also disclosed herein.

Arf6 inhibitors and methods of synthesis and use thereof

The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L, L, are as defined herein.

Purine-core inhibitors of HSP90 and their use in treating cancer

The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders such as cancer.

Therapeutic compounds and uses thereof

The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.

Therapeutic compounds and their use in cancer

Compounds and pharmaceutical compositions containing the same are provided, which are useful in therapeutic treatment or prevention of various diseases.

Compounds, compositions, and methods employing same

The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &#x3b2;-aryl-&#x3b1;-oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them 

Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents

Tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them

Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them

Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them

Growing community of inventors

Salt Lake City, UT, United States of America

Ashok Bajji